Paclitaxel is a part of the first-line adjuvant chemotherapeutic treatment of endometrial carcinoma [39,40], while trastuzumab is an antibody targeting human epidermal growth factor 2 (HER2) that has been used for selected patients with endometrial carcinoma [41]. Here, ERBB2 is linked to endometrial carcinoma.